Skip to main content
800-TEMPLE-MED Schedule Appointment
SEARCH TEMPLE HEALTH

Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE

view all Clinical Trials

Overview

This is a multicenter, randomized (1:1 inhaled treprostinil: placebo), double-blinded, placebo-controlled trial to evaluate the safety and efficacy of inhaled treprostinil in subjects with pre-capillary pulmonary hypertension (PH) associated with interstitial lung disease (ILD) including combined pulmonary fibrosis and emphysema (CPFE). The study will include about 314 patients at approximately 100 clinical trial centers. The treatment phase of the study will last approximately 16 weeks. Patients who complete all required assessments will also be eligible to enter an open-label, extension study (RIN-PH-202).

Contact

For more information about this trial or to inquire about eligibility, email breathe@temple.edu or call 215-707-1359.